Anti-cleaved PARP1 antibody [EPR34-46] - BSA and Azide free (Capture),Abcam,AB315131
ab315131 is a BSA and Azide free antibody supplied in an unconjugated format and it is suitable for sandwich ELISAs to quantify Human cleaved PARP1. The recommended pair for sandwich ELISA is: Capture: ab315131, Human cleaved PARP1 Capture Antibody (unconjugated) Detector: ab315132 , Human PARP1 Detector Antibody (unconjugated) The reference range value is 0.63-40 ng/mL. The recommended antibody orientation is based on internal optimization for ELISA based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Please note that the range provided for this antibody is only an estimation based on the performance of the product using the recommended antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody in your assay. Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency. The antibodies are provided at an approximate concentration of 1 mg/ml as measured by the protein A280 method. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Sandwich ELISA The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Please note that the range provided for this antibody is only an estimation based on the performance of the product using the recommended antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody in your assay. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Host
Rabbit
Reactivity
Human
Application
sELISA
Platform ID
BAB201636255
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair (PubMed : 17177976, PubMed : 18055453, PubMed : 18172500, PubMed : 19344625, PubMed : 19661379, PubMed : 20388712, PubMed : 21680843, PubMed : 22582261, PubMed : 23230272, PubMed : 25043379, PubMed : 26344098, PubMed : 26626479, PubMed : 26626480, PubMed : 30104678, PubMed : 31796734, PubMed : 32028527, PubMed : 32241924, PubMed : 32358582, PubMed : 33186521, PubMed : 34465625, PubMed : 34737271). Mediates glutamate, aspartate, serine, histidine or tyrosine ADP-ribosylation of proteins : the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of target residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units (PubMed : 19764761, PubMed : 25043379, PubMed : 28190768, PubMed : 29954836, PubMed : 35393539, PubMed : 7852410, PubMed : 9315851). Serine ADP-ribosylation of proteins constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage (PubMed : 33186521, PubMed : 34874266). Specificity for the different amino acids is conferred by interacting factors, such as HPF1 and NMNAT1 (PubMed : 28190768, PubMed : 29954836, PubMed : 32028527, PubMed : 33186521, PubMed : 33589610, PubMed : 34625544, PubMed : 34874266). Following interaction with HPF1, catalyzes serine ADP-ribosylation of target proteins; HPF1 confers serine specificity by completing the PARP1 active site (PubMed : 28190768, PubMed : 29954836, PubMed : 32028527, PubMed : 33186521, PubMed : 33589610, PubMed : 34625544, PubMed : 34874266). Also catalyzes tyrosine ADP-ribosylation of target proteins following interaction with HPF1 (PubMed : 29954836, PubMed : 30257210). Following interaction with NMNAT1, catalyzes glutamate and aspartate ADP-ribosylation of target proteins; NMNAT1 confers glutamate and aspartate specificity (By similarity). PARP1 initiates the repair of DNA breaks : recognizes and binds DNA breaks within chromatin and recruits HPF1, licensing serine ADP-ribosylation of target proteins, such as histones (H2BS6ADPr and H3S10ADPr), thereby promoting decompaction of chromatin and the recruitment of repair factors leading to the reparation of DNA strand breaks (PubMed : 17177976, PubMed : 18172500, PubMed : 19344625, PubMed : 19661379, PubMed : 23230272, PubMed : 27067600, PubMed : 34465625, PubMed : 34874266). HPF1 initiates serine ADP-ribosylation but restricts the polymerase activity of PARP1 in order to limit the length of poly-ADP-ribose chains (PubMed : 33683197, PubMed : 34732825, PubMed : 34795260). In addition to base excision repair (BER) pathway, also involved in double-strand breaks (DSBs) repair : together with TIMELESS, accumulates at DNA damage sites and promotes homologous recombination repair by mediating poly-ADP-ribosylation (PubMed : 26344098, PubMed : 30356214). Mediates the poly-ADP-ribosylation of a number of proteins, including itself, APLF, CHFR, RPA1 and NFAT5 (PubMed : 17396150, PubMed : 19764761, PubMed : 24906880, PubMed : 34049076). In addition to proteins, also able to ADP-ribosylate DNA : catalyzes ADP-ribosylation of DNA strand break termini containing terminal phosphates and a 2'-OH group in single- and double-stranded DNA, respectively (PubMed : 27471034). Required for PARP9 and DTX3L recruitment to DNA damage sites (PubMed : 23230272). PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites (PubMed : 23230272). PARP1-mediated DNA repair in neurons plays a role in sleep : senses DNA damage in neurons and promotes sleep, facilitating efficient DNA repair (By similarity). In addition to DNA repair, also involved in other processes, such as transcription regulation, programmed cell death, membrane repair, adipogenesis and innate immunity (PubMed : 15607977, PubMed : 17177976, PubMed : 19344625, PubMed : 27256882, PubMed : 32315358, PubMed : 32844745, PubMed : 35124853, PubMed : 35393539, PubMed : 35460603). Acts as a repressor of transcription : binds to nucleosomes and modulates chromatin structure in a manner similar to histone H1, thereby altering RNA polymerase II (PubMed : 15607977, PubMed : 22464733). Acts both as a positive and negative regulator of transcription elongation, depending on the context (PubMed : 27256882, PubMed : 35393539). Acts as a positive regulator of transcription elongation by mediating poly-ADP-ribosylation of NELFE, preventing RNA-binding activity of NELFE and relieving transcription pausing (PubMed : 27256882). Acts as a negative regulator of transcription elongation in response to DNA damage by catalyzing poly-ADP-ribosylation of CCNT1, disrupting the phase separation activity of CCNT1 and subsequent activation of CDK9 (PubMed : 35393539). Involved in replication fork progression following interaction with CARM1 : mediates poly-ADP-ribosylation at replication forks, slowing fork progression (PubMed : 33412112). Poly-ADP-ribose chains generated by PARP1 also play a role in poly-ADP-ribose-dependent cell death, a process named parthanatos (By similarity). Also acts as a negative regulator of the cGAS-STING pathway (PubMed : 32315358, PubMed : 32844745, PubMed : 35460603). Acts by mediating poly-ADP-ribosylation of CGAS : PARP1 translocates into the cytosol following phosphorylation by PRKDC and catalyzes poly-ADP-ribosylation and inactivation of CGAS (PubMed : 35460603). Acts as a negative regulator of adipogenesis : catalyzes poly-ADP-ribosylation of histone H2B on 'Glu-35' (H2BE35ADPr) following interaction with NMNAT1, inhibiting phosphorylation of H2B at 'Ser-36' (H2BS36ph), thereby blocking expression of pro-adipogenetic genes (By similarity). Involved in the synthesis of ATP in the nucleus, together with NMNAT1, PARG and NUDT5 (PubMed : 27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed : 27257257).. Poly [ADP-ribose] polymerase 1, processed C-terminus. Promotes AIFM1-mediated apoptosis (PubMed : 33168626). This form, which translocates into the cytoplasm following cleavage by caspase-3 (CASP3) and caspase-7 (CASP7) in response to apoptosis, is auto-poly-ADP-ribosylated and serves as a poly-ADP-ribose carrier to induce AIFM1-mediated apoptosis (PubMed : 33168626).. Poly [ADP-ribose] polymerase 1, processed N-terminus. This cleavage form irreversibly binds to DNA breaks and interferes with DNA repair, promoting DNA damage-induced apoptosis. See full target information PARP1
Category Paths
Please provide the required information below so that we can quickly source your products.